Key facts
- Eyconis’s last known valuation is $160.5M (Jan 2024).
- It has raised $85.3M across 2 recorded rounds; the latest was Early Stage VC ($25.0M) in Oct 2025.
- Notable investors include RA Capital Management, Frazier Healthcare Partners, HealthQuest Capital, venBio.
- Eyconis has filed 1 Form D with the SEC, most recently Feb 2024 ($60.3M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Eyconis
Funding rounds
2 roundsAbout Eyconis
Developer of ophthalmology products designed to improve ophthalmology treatments. The company is focused on developing, manufacturing, and commercializing transcon ophthalmology assets globally, enabling clients to leverage the therapies for retinal diseases, such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA).
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2023
- Employees
- 39
- Website
- eyconis.com/
- Ownership
- Privately Held (backing)
Eyconis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eyconis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eyconis in its N-PORT filings yet. We sweep new filings monthly.